Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool February 25, 2008 Brian Orelli	The Biologic That Keeps on Giving Just a month after Abbott Laboratories receives a fifth approval for its anti-inflammatory Humira, the FDA approved the biotech drug to treat yet another disease.
The Motley Fool May 11, 2011 Brian Orelli	Abbott's Lucky Number Seven might be Abbott Labs' Humira's lucky number. The anti-inflammatory is up for approval in its seventh indication and the data looks pretty good.
The Motley Fool January 24, 2008 Brian Orelli	Abbott Goes Global The drugmaker wraps up a solid 2007 with successful expansion overseas.
Pharmaceutical Executive February 1, 2012 Ben Comer	Best to Market Pharm Exec's Brand of the Year: Abbott's Humira
The Motley Fool April 12, 2004 Brian Gorman	Abbott Not Rewarded Abbott Laboratories first-quarter earnings news was positive, but investors didn't react enthusiastically.
The Motley Fool June 22, 2011 Brian Orelli	In-Licensing to the Rescue Abbott's latest deal could help shore things up.
The Motley Fool February 10, 2004 David Nierengarten	The Psoriasis Wars The pharma heavies are battling for the chronic skin disease's market.
The Motley Fool July 15, 2009 Brian Orelli	Less Inflammation From Abbott's Quarter Humira is headed back in the right direction.
The Motley Fool October 14, 2009 Brian Orelli	Consistency Makes This Stock a Winner Abbott turns in a solid quarter, but it needs to keep branching out.
Pharmaceutical Executive February 1, 2012 William Looney	Brand Success: It's Not Serendipity A new generation of products for inflammatory disease is coming forward, promising better promise and possibly a cure.
The Motley Fool April 17, 2008 Brian Orelli	Abbott's Not Ailing Abbott produces double-digit growth; investors yawn.
The Motley Fool April 13, 2011 Brian Orelli	Abbott's Potential Billion-Dollar Problem Abbott's Humira forms antibodies in nearly a quarter of patients.
The Motley Fool November 21, 2007 Brian Lawler	Elan and Biogen Denied Elan's multiple sclerosis treatment is denied a label expansion in Europe. Investors, take note.
The Motley Fool October 18, 2006 Brian Lawler	Is a Buyback the Best Abbott Can Do? Abbott Labs may be out of ideas for its cash. Investors, take note.
The Motley Fool June 17, 2004 Brian Gorman	Genentech's Unique Drug Genentech and Biogen Idec's Phase II trial demonstrating Rituxan's effectiveness in treating moderate-to-severe rheumatoid arthritis was enshrined in the prestigious pages of the New England Journal of Medicine, adding heft to the study's results.
The Motley Fool September 19, 2008 Brian Orelli	Skinning the Competition J&J's psoriasis drug candidate beats Amgen and Wyeth's Enbrel.
The Motley Fool June 25, 2007 Brian Orelli	Leading the Pack of Follow-On Drug Makers Generic drug maker Dr. Reddy's Laboratories is taking a huge risk to get ahead of the pack, but it's well worth the rewards of being in front of its competitors. Investors, take note.
The Motley Fool September 23, 2008 Brian Lawler	Will Generic Biologics Get Special Treatment? While the rest of the market was lost in the financial meltdown, a little-noticed report discussing some of the biopharmaceutical bills going through Congress was released.
The Motley Fool January 16, 2008 Brian Lawler	More Tysabri on the Way Biogen and Elan receive an additional approval for Tysabri. Investors, take note.
The Motley Fool December 2, 2009 Brian Orelli	Tired of Waiting, Teva Advances Teva Pharmaceutical decides it's not worth waiting for the U.S. government to establish a pathway for approval of generic versions of biologic drugs. Instead, it's asking for approval for its copycat of Amgen's Neupogen under the normal branded-drug process.
The Motley Fool June 17, 2009 Brian Orelli	Savient Saves and Moves Up The FDA advisory panel gives Savient's Krystexxa a passing grade.
The Motley Fool July 23, 2007 Brian Lawler	A Setback for Elan and Biogen Elan and Biogen receive negative news about Tysabri. The EU medical authorities won't allow its use as a treatment for Crohn's disease.
The Motley Fool March 3, 2009 Brian Orelli	Stop Worrying About Follow-On Biologics They're inevitable, but they won't hurt biotech as much as you might think.
The Motley Fool September 28, 2009 Rick Aristotle Munarriz	Abbott Labs Looks Less Lopsided Abbott Labs' $6.6 billion purchase of Solvay's pharmaceuticals business is just what the doctor ordered.
The Motley Fool October 4, 2007 Brian Orelli	Stopping the Inflammation Johnson & Johnson subsidiary Centocor announces positive phase 3 data for its psoriasis drug. Given the strong results from the trial, the company plans to file a marketing application for the drug by the end of the year.
The Motley Fool January 27, 2010 Brian Orelli	Humira or Not, Abbott's on a Roll Investors worry about how Abbott's Humira is such a large fraction of the company's revenue, and then when the company turns in a nice quarter even without strong U.S. sales of Humira, they complain about that.
The Motley Fool October 26, 2007 Brian Orelli	Investing in Follow-On Biologics Investors, while approvals of follow-on biologics in the U.S. are probably still years away, now is the time to do your research. Those that are leading the race overseas are likely to be first in line when the FDA opens its door to applications.
The Motley Fool April 1, 2004 Charly Travers	Atrix Batting 1.000 Atrix Laboratories' drugs have breezed past the Food and Drug Administration.
The Motley Fool January 27, 2011 Brian Orelli	Abbott Labs: Growth in All the Wrong Places Abbott's a solid company with solid dividend and growth potential in the near term. But investors need to be careful extrapolating that growth out.
The Motley Fool February 20, 2008 Brian Orelli	Abbott's Copycat Combinations Abbott's latest FDA approval is for Simcor, a combination of Niaspan -- Abbott's slow-release niacin -- and the active component of Merck's Zocor, which isn't patent-protected anymore. Investors take note.
The Motley Fool November 4, 2008 Brian Orelli	Does the Supreme Court Control Your Investment? The Supreme Court is about to make a decision that could affect drug company investors.
Pharmaceutical Executive December 1, 2011 Lujing Wang	The Payoff for Payers Thorough risk assessment is essential before placing bets on good evidence that clears a path to approval.
The Motley Fool August 1, 2007 Brian Lawler	Elan Gets a Vote of Confidence Elan receives some good news from an FDA advisory panel in the form of a recommendation to expand the use of Tysabri to treat Crohn's disease.
The Motley Fool June 30, 2009 Brian Orelli	Johnson & Johnson Inflames Abbott $1.67 billion is one hefty reward.
The Motley Fool April 24, 2009 Brian Orelli	The Economy Strikes Again Amgen isn't recession-proof either.
Chemistry World September 11, 2013 Phillip Broadwith	First biosimilar antibody drugs approved in Europe The European commission has given final marketing approval to the first generic versions of monoclonal antibody drug infliximab (Johnson & Johnson's Remicade).
The Motley Fool October 8, 2010 Brian Orelli	Pfizer's Rash (of Bad News) Is Over Data from Pfizer's phase 2 trial testing tasocitinib against psoriasis, a painful autoimmune skin disease, looks promising even given its small size.
The Motley Fool April 27, 2009 Brian Orelli	Johnson & Johnson's Simponi Sticks to the Wall Johnson & Johnson gets its second-generation TNF-alpha inhibitor past the FDA.
The Motley Fool February 22, 2011 Brian Orelli	A Billion-Dollar Market to Open "Very Soon" Biosimilar drugs are finally coming to the U.S.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool June 3, 2009 Brian Orelli	No More Triple-Digit Returns? If FDA decisions could be predicted easily, investors might not get to enjoy triple-digit returns, so perhaps we shouldn't be too upset about the tight-lipped nature of the FDA.
The Motley Fool July 9, 2004 Phil Wohl	Abbott Labs Concocts Strong Q2 The drug maker reports earnings as expected and refines its third-quarter guidance.
The Motley Fool September 28, 2009 Brian Orelli	J&J's Knockout Drug J&J's Psoriasis drug Stelara beat Amgen's and Wyeth's Enbrel in a head-to-head competition, and considering the efficacy data, it shouldn't have much problems competing against the other psoriasis drugs.
The Motley Fool October 20, 2011 Brian Orelli	Mini J&J? I Guess Not Abbott says it plans to split in two: drugs in one company, everything else in the other.
The Motley Fool June 5, 2008 Brian Lawler	Cancer Concerns Fuel FDA Inquiry The agency examines a class of blockbuster drugs for a link to cancer in young patients.
The Motley Fool April 19, 2006 Stephen D. Simpson	Abbott Gets By Will the acquisition of Guidant's vascular business kick-start this story? Abbott has shown a pretty reliable trend of getting cheap enough to buy at least once a year. Of course, the downside to that is that the stock really hasn't gone anywhere in those seven years.
BusinessWeek March 14, 2005 Arnst & Barrett	Another Ailing Miracle Drug Biogen's troubles with Tysabri are a setback for immune-system treatments
The Motley Fool July 29, 2010 Brian Orelli	Is Abbott a Buy? Whether or not Abbott is a buy depends on management's ability to transition the company.
The Motley Fool June 16, 2008 Brian Orelli	More Cancer Issues for Johnson & Johnson Potential cancer-causing side effects of Johnson & Johnson's drugs are like a tumor that continues to grow on the company.
The Motley Fool October 22, 2009 Brian Orelli	Good Luck in 2010, Amgen Just when it looked like Amgen was turning things around the Food and Drug Administration threw a wrench in the biotech's plans for its osteoporosis drug Prolia.